In fact, the stocks of medical companies around the world have been affected, whether they have anti-cancer business or not.
Healthcare stocks are falling globally.
But [Four-Armed King Kong] easily made 20 billion U.S. dollars in profits and returned them to China.
Twenty billion U.S. dollars is certainly not much.
It is not as big as the hundreds of billions of dollars in profits that Wu Siyuan gained from shorting U.S. stocks before.
But this [not too much] also depends on who you compare with.
Twenty billion U.S. dollars is enough to be on the "Forbes Rich List."
Turn your attention back to the country.
The heat caused by the [ledimumab] incident is getting bigger and bigger (harvest completed).
[Xuanhu Technology] finally stepped forward and announced to the outside world the clinical trial results that took just over a month.
Anti-cancer drugs mainly look at several indicators - OS, PFS, ORR.
Tumor OS refers to the overall survival time of tumor patients.
OS is the abbreviation of Overall surviva in English. In randomized controlled studies, tumor OS refers to the time from randomization to patient death due to any reason.
Tumor OS data is often considered the best endpoint for determining efficacy in tumor-related clinical trials.
In clinical studies, if it is proven that a new drug can improve overall survival, it is often more meaningful than other research endpoints. Only when a drug is finally proven to be able to prolong overall survival can it ultimately change treatment practice and modify the current
Clinical Guidelines.
In other words, if you want to judge whether a new anti-tumor drug is effective and how much benefit it can bring to patients, the extension of overall survival time is the hard truth and the gold standard. It is also the key for researchers to study an anti-tumor drug.
Final requirements for new cancer drugs.
After anti-tumor treatment, obtaining patient OS often requires long-term follow-up of a large sample of people.
Of course, [Xuanhu Technology]’s [ledimumab] experiment has only lasted for more than a month, and the OS can’t see anything.
Then comes PFS!
PFS is one of the indicators for judging the survival rate of patients with malignant tumors.
PFS refers to progression-free survival time, which can be used to judge the efficacy of drugs in tumor treatment and can be used as the primary endpoint or secondary endpoint of clinical drug development trials.
Usually refers to the time between the start of treatment and the progression or death of patients with malignant tumors.
Sometimes, PFS is used together with overall survival time as an indicator to evaluate the efficacy of anti-tumor drugs.
This data requires long-term experimental time to statistically produce more meaningful results.
The trial period of [ledimumab] was only more than a month.
There have been many cases where no cancer cells were detected in the body, but with the current level of technology in the real world, there is no guarantee whether all the cancer cells in the cases have been eliminated.
Therefore, this PFS cannot produce accurate data.
Again, the clinical trials were too short and many data could not be counted.
Another one is ORR!
Tumor ORR refers to the objective response rate. In academic terms, it is the proportion of patients whose tumor volume is reduced by 30% and maintained for more than 4 weeks, that is, the sum of the proportions of complete response (CR) and partial response (PR). The higher the ORR, the higher the ratio.
The more patients achieve tumor shrinkage using this treatment method.
In layman's terms, it is the proportion of patients who are effective after receiving a certain treatment. The higher the ORR, the more patients whose tumors shrink using this therapy.
The most intuitive way to determine whether a patient's treatment is effective is to see whether and how much the tumor has shrunk. Of course, the ideal situation is that the tumor disappears after treatment.
If the tumor still increases by more than 20% or new masses appear after treatment, the treatment plan has failed; if the tumor shrinks by more than 30% and is still shrunk by more than 30% during a follow-up examination 4 weeks later, it means that the treatment is effective.
ORR reflects the probability of tumor shrinkage or elimination after tumor drug treatment. For example, ORR=20% means that 20% of patients have complete or partial tumor disappearance after treatment.
However, ORR has a shortcoming, that is, it reflects the efficacy results of each treatment evaluation point and cannot answer the patient's entire efficacy benefit process, such as extending the life span by several months, so other indicators are needed to supplement it.
ORR data is one of the few data that [Xuanhu Technology] currently has available to the outside world.
And this data is 100%!
Yes, the objective sustained release rate of [ledibizumab] is 100%.
For patients with advanced cancers of various types who join the experimental group and receive the real [leditimab] instead of a placebo, the objective sustained release rate of taking [leditizumab] is 100%.
Moreover, what is even more exaggerated is that after one month of taking [redizumab], the tumor shrinkage effect was the worst, reaching more than 60%, and according to the latest test results, the tumor area was still
In the continuous shrinkage, whether it is the original tumor lesion or metastatic lesion.
Among the patients with the best results, their tumors could no longer be detected. After supplementing their nutrition, their bodies looked like normal people. Of course, the original permanent damage caused by the tumors to certain organs of the body has not been confirmed.
It can no longer be restored.
………………………………………………………………………………………………………………………………
………
[Xuanhu Technology] mainly publishes this ORR data:
All experimenters who were not members of the placebo group responded, with an objective sustained release rate of 100%.
At the same time, there are a few words announced to the public:
[Redizumab] responded to all types of cancer in all participants.
No side effects have been found so far.
The preliminary efficacy analysis is very encouraging!
………………………………………………………………………………………………………………………………
…
[Xuanhu Technology] As soon as this official news came out.
Public opinion around the world exploded.
The whole world's attention is focused on this place.
Not just eyes are turned here.
Cancer patients around the world, especially those with advanced cancer, are frantically applying to enter China and requesting supplies of ledizumab.
The International Health Organization attaches great importance to this matter and has sent a large number of officials to intervene.
This is no longer a simple medical matter, but has risen to a political level.
China naturally attaches great importance to it.
Of course, they also pay attention to the domestic situation.
After [Xuanhu Technology] announced this [clinical data], many cancer patients in China also looked crazy.
It wasn't certain before, but now it's official.
They are trying every possible means to obtain the anti-cancer drug [leditimab], no, it should be said to be the [magic drug for cancer treatment]!
Especially those terminal-stage cancer patients and their families are even more crazy.
Because patients in the terminal stage are really racing against death every day. They don’t know what will happen, but tumor complications will occur and they will die.
They are eager to get this drug as early as possible.